Top 20 big pharma saw 3.4% market cap decline in Q1

20 April 2023

The world’s top 20 biopharma companies reported a drop in their combined market capitalization by 3.4% from $3.61 trillion at the end of 2022, to $3.49 trillion after the first three months of 2023.

GlobalData, the data and analytics company, has crunched the numbers and analyzed the findings, which it attributes to the challenging current macroeconomic environment of high inflation and increasing capital costs.

A decrease in market capitalization was indicated for 12 of the top 20 players from the end of one quarter to the next, GlobalData found. The other eight did experience growth, with Germany’s Bayer (BAYN: DE) reporting the healthiest rise at more than 23%, followed by Danish drugmaker Novo Nordisk (NOV: N), which saw an 18% jump.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK